pityriasis%20(tinea)%20versicolor
PITYRIASIS (TINEA) VERSICOLOR
Pityriasis (Tinea) versicolor is a fungal infection caused by Malassezia furfur. It is benign, superficial, and localized to the stratum corneum.
It may present as chronic or recurrent infection and may occur in healthy individuals.
It is more common in summer than winter months.
It presents with multiple well-demarcated macules or patches and finely scaled plaques with hypopigmentation or hyperpigmentation, hence the term "versicolor".
Lesions are usually found on the upper trunk, chest, back and shoulders, and may extend toward the neck, face and arms.

Definition

  • Pityriasis (tinea) versicolor is a common, benign, superficial fungal infection localized to the stratum corneum

Etiology

  • Caused by lipophilic yeasts, Malassezia species, part of the normal flora of the human skin

Signs and Symptoms

  • May present as chronic or recurrent infection & may occur in healthy individuals
    • More common in summer than winter months
  • Predominates in young adults when the sebaceous glands are most active
  • Presents w/ multiple well-demarcated macules or patches & finely scaled plaques w/ hypopigmentation orhyperpigmentation, hence the term “versicolor”
  • Tends to be asymptomatic & is mainly a cosmetic concern but pruritus may or may not be present
  • Usually found on the upper trunk, chest, back & shoulders, & may extend towards the neck, face & arms
  • Lesions do not tan along the normal skin

Risk Factors

Risk Factors that Promote Pityriasis (Tinea) Versicolor Infection:

  • High temperature & high humidity
    • Prominent in tropical & subtropical regions
  • Occlusive clothing
  • Oily skin or application of oils to skin
  • Excessive sweating
  • Immunocompromised state, malnutrition & hereditary predisposition
  • Oral corticosteroid intake or Cushing’s disease
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.